Monoamine oxidase inhibitors

Monoamine oxidase inhibitors are the fellowship drug class that separates candidates who can recite "avoid cheese" from those who can run a safe TRD pathway. Examiners stress classification, tyramine pharmacology, washout arithmetic, serotonin toxicity pairs, and the selegiline patch dose–diet interaction. Under-use is real; reckless use is examinable malpractice.[1][2][3][11]

Definition and classification

An MAOI antidepressant inhibits monoamine oxidase enzymes that catabolise serotonin, noradrenaline, dopamine and dietary monoamines such as tyramine. Clinical antidepressant effect tracks mainly MAO-A inhibition in the central nervous system; gut and hepatic MAO-A are the safety valve that normally destroys dietary tyramine before it can act as a pressor amine.[2][12]

Chemistry trivia examiners still ask: hydrazine agents (phenelzine, isocarboxazid) versus non-hydrazine tranylcypromine (more activating; amphetamine-like structural flavour without equating them clinically).[1][2]

Epidemiology and place in care

MAOIs were among the first effective antidepressants and then fell from routine first-line use as SSRIs arrived with simpler safety narratives. Contemporary reviews document under-prescribing relative to residual efficacy in atypical depression and treatment-resistant depression (TRD), often because clinicians never learned practical diet and interaction management.[2][3]

STAR*D multi-step data show that remission falls as failed trials accumulate; late pathways including MAOI are hard, not obsolete. McGrath and colleagues compared tranylcypromine with venlafaxine plus mirtazapine after three failed medication trials — remission was low in both arms, reinforcing specialist intensity rather than casual MAOI improvisation.[5][6]

These are orientation anchors from landmark trials and standard product-safety teaching — always confirm current local product information.[4][5][7][8][1]

Pathophysiology — MAO isoforms and the cheese reaction

MAO-A preferentially deaminates serotonin, noradrenaline and tyramine. MAO-B handles phenylethylamine and shares dopamine. Irreversible inhibitors covalently inactivate enzyme; recovery requires new enzyme synthesis over roughly two weeks, which is why washouts are measured in weeks, not half-lives of the tablet alone.[2][12]

Tyramine hypertensive crisis ("cheese reaction"). Dietary tyramine is normally destroyed by gut and hepatic MAO-A. With irreversible nonselective inhibition, absorbed tyramine displaces noradrenaline from sympathetic terminals, producing acute hypertension, severe headache, and risk of intracranial haemorrhage. Risk is dose-related to tyramine load, not mystical — modern analytical work refined which foods truly exceed dangerous per-serving thresholds.[10][11][12]

RIMA logic. Reversible competitive MAO-A inhibitors can be displaced by high substrate loads, giving a pharmacological safety buffer against tyramine compared with irreversible agents, while retaining antidepressant utility in meta-analysis versus TCA comparators for moclobemide-class drugs.[9][12]

Selegiline patch logic. Transdermal delivery aims for CNS MAO inhibition while reducing first-pass gut MAO-A inhibition at the lowest approved antidepressant patch dose, supporting trials that treated MDD without routine dietary restriction at that dose level — higher patch doses reintroduce dietary caution in labelling teaching.[7][8][12]

Clinical indications and presentation context

Primary exam indications:

1. Treatment-resistant unipolar depression after adequate failed trials, within a specialist TRD pathway (augmentation, switch, ECT consideration as parallel options).[1][5][16][17]
2. Atypical depression — mood reactivity with rejection sensitivity, leaden paralysis, hypersomnia and hyperphagia historically showed preferential response to phenelzine over imipramine in the Columbia group programme; Liebowitz 1988 remains the classic stem.[4]
3. Selected anxiety spectrum uses (jurisdiction-dependent), especially moclobemide where licensed for social anxiety in some regions — always check local product labels.[2][9]

MAOIs are not the default first tablet for uncomplicated mild–moderate MDD in stepped-care systems that favour psychological therapy and safer first-line antidepressants.[16][17][18]

Assessment before prescribing

Before the first irreversible MAOI dose, document: confirmed unipolar (or carefully formulated) diagnosis and bipolar screen; full medicine and OTC list including cold remedies with dextromethorphan or sympathomimetics, tramadol, pethidine, other opioids, triptans, stimulants, St John's wort and other antidepressants; capacity and practical ability to follow diet and interaction rules with written materials and pharmacy flag; baseline lying and standing BP, weight, sexual function, suicide risk and means access, and pregnancy potential; and an emergency plan for severe headache or neurological symptoms after restricted foods. Prescribing without a diet and interaction education plan is incomplete care, not elegant minimalism.[1][11][12]

Investigations

No routine plasma level monitoring is required for classic MAOIs in most services. Obtain general psychotropic baseline as indicated (U&E, LFT, ECG if cardiac risk or older adult, pregnancy test). In crisis: continuous BP and ECG for hypertensive emergencies; serotonin toxicity remains a clinical diagnosis using Hunter decision rules when a serotonergic agent is present.[14][15][1]

Definitive management — agents, doses, monitoring

Doses below are exam orientation ranges for adults; start low, titrate slowly, individualise, and verify current product information and local formulary. Older adults need lower starts and slower titration because of orthostasis.[1][2][17]

Adequate trial. Therapeutic dose for typically 4–8 weeks with adherence, diet compliance, and measurement-based symptom tracking before declaring failure. Pseudo-resistance still applies: wrong diagnosis, substances, non-adherence, under-dosing from fear of side-effects.[1][6][16]

Selegiline transdermal system. Bodkin and Amsterdam demonstrated short-term antidepressant efficacy versus placebo. Amsterdam's 2003 trial specifically studied the system without dietary restrictions in the protocol design, supporting the low-dose dietary teaching that examiners still test: relaxed tyramine diet mainly at 6 mg/24 h; reimpose restrictions at 9–12 mg/24 h per product labelling logic. Drug–drug serotonergic prohibitions still apply at all doses.[7][8][1]

Tyramine diet — modern, not folklore

Analytical work by Walker, Shulman and colleagues refined which foods actually deliver high tyramine per serving (for example aged or poorly stored high-risk items such as certain aged cheeses, some fermented/cured products, soy sauce in quantity, yeast extracts, spoiled protein). Modern prescriber diet guides emphasise high-tyramine aged/fermented/spoiled foods, portion and storage, and practical patient language rather than endless forbidden lists that destroy adherence.[10][11]

Absolute teaching set (classic irreversible MAOI): aged cheeses, cured/aged meats, draft (tap) beer, concentrated yeast extracts, soy sauce in significant amounts, improperly stored protein foods, and other high-tyramine fermented products. Fresh foods prepared and refrigerated properly are far safer than historical scare-lists suggested. Continue diet restrictions for about two weeks after stopping an irreversible MAOI while enzyme regenerates.[10][11][12]

Washouts and switching — non-negotiable arithmetic

Standard exam teaching (always confirm product information): most SSRI/SNRI/TCA → irreversible MAOI about 2 weeks after stop; fluoxetine → irreversible MAOI about 5 weeks (long half-life norfluoxetine); irreversible MAOI → SSRI/SNRI/other serotonergic antidepressant about 2 weeks after stop; moclobemide switches use shorter product-specific horizons than irreversible agents but must still be planned — do not freestyle. Cross-taper into an irreversible MAOI from an SSRI is an exam fail. Direct combination of irreversible MAOI with SSRI, SNRI, clomipramine or imipramine is a classic cause of severe serotonin toxicity.[1][12][14]

Drug interactions — two lethal pathways

Pathway map synthesises MAOI interaction reviews, serotonin toxicity literature and selegiline patch trial labelling teaching.[7][8][12][13][14]

Serotonergic high-risk partners: SSRIs, SNRIs, clomipramine, imipramine, St John's wort, linezolid (MAOI antibiotic context), methylene blue (specialist perioperative), and opioids with significant serotonin reuptake effects — especially pethidine (meperidine), tramadol and dextromethorphan. Gillman's anaesthesia-focused review is the standard citation for MAOI–opioid serotonin toxicity literacy; morphine-class agents without strong SRI activity are relatively preferred when analgesia is essential and coordinated.[13][14][12]

Serotonin toxicity is diagnosed clinically. Boyer and Shannon describe the triad of altered mental status, autonomic hyperactivity and neuromuscular excitation. Hunter Serotonin Toxicity Criteria improve specificity in the presence of a serotonergic agent (spontaneous clonus; inducible clonus plus agitation or diaphoresis; ocular clonus plus agitation or diaphoresis; tremor plus hyperreflexia; or hypertonia with temperature above 38°C plus ocular/inducible clonus — quote the published rules, not improvisation).[14][15]

Management principles: stop offending agents; ABC; benzodiazepines for agitation; active cooling; cyproheptadine in specialist protocols; ICU for severe hyperthermia and rigidity. Differentiate from NMS (dopamine-blocker context, bradyreflexia/lead-pipe pattern) and from pure tyramine crisis (pressor picture without the serotonergic neuromuscular signature).[14][15]

Hypertensive crisis management: emergency department pathway — continuous BP monitoring, short-acting parenteral antihypertensives per local protocol (historical teaching often names phentolamine; modern practice uses protocol-driven agents), stop ongoing tyramine exposure, evaluate for end-organ damage. Do not treat every headache as anxiety after aged cheese on an MAOI.[11][12]

Adverse effects beyond crises

Common and important non-crisis effects: orthostatic hypotension (especially phenelzine — check postural BP), dizziness, insomnia or activation (tranylcypromine), daytime sedation, weight gain, sexual dysfunction, oedema, myoclonus, and rare hepatotoxicity concerns with hydrazine agents. Sexual side-effects still matter for adherence even when the class is chosen for TRD. Early activation and suicide risk review apply as for any antidepressant start or dose increase.[1][2][3]

Special scenarios

Perioperative care. Coordinate with anaesthesia early. Avoid serotonergic opioids; plan holding and restart with washout awareness; do not assume the surgical team knows the MAOI list.[13][1]

Overdose. MAOI overdose can produce delayed severe toxicity — prolonged observation, supportive care, and interaction vigilance. This is an ED/toxicology interface, not a brief ED discharge without observation plans when significant ingestion is suspected.[12][14]

RIMA practice. Moclobemide meta-analysis supports efficacy comparable to TCAs with better average tolerability than older agents in that evidence set. Still counsel on high-tyramine extremes and serotonergic combinations; "safer diet" is not "no rules".[9][2]

Special populations

Older adults. Start very low; orthostasis and falls dominate risk; polypharmacy multiplies interaction chance.[2][1]

Youth. Limited evidence base for classic MAOIs; if ever considered, specialist setting with intensive monitoring — not routine CAMHS first-line.[16]

Pregnancy and lactation. Generally avoid classic MAOIs unless a perinatal specialist pathway judges residual benefit after failed safer options in severe TRD; untreated severe depression also harms. Coordinate obstetrics and perinatal psychiatry; never stop abruptly without a plan.[16][17]

Parkinson disease. Oral selegiline as MAO-B adjunct is a neurology dosing context distinct from antidepressant transdermal dosing for MDD — do not conflate in the viva.[2][7]

Prognosis and disposition

When used correctly in TRD or atypical depression, meaningful response is possible and historically under-offered. Continuation after response follows general antidepressant maintenance logic within a higher-intensity specialist follow-up model. Disposition should include written diet card, pharmacy alert, crisis contacts, and clear instructions for headache after restricted foods.[1][4][5][6]

Evidence, guidelines and regional deltas

Exam pearls

• 2 / 5 / 2: ~2 weeks most antidepressants → MAOI; ~5 weeks after fluoxetine; ~2 weeks MAOI → SSRI/SNRI.[1][12]
• Pethidine + MAOI and tramadol + MAOI are automatic fail stems.[13]
• Atypical depression → phenelzine historical preferential response (Liebowitz).[4]
• Patch 6 mg/24 h diet exception teaching; 9–12 mg reintroduce diet; serotonergic drug bans at all doses.[7][8]
• Cheese reaction ≠ serotonin syndrome — different mechanism, different co-triggers, overlapping emergency urgency.[11][14]
• Written diet + pharmacy alert are part of the prescription.[1][11]

References

1. [1]Van den Eynde V, Abdelmoemin WR, Abraham MM, et al. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr, 2023.PMID 35837681
2. [2]Shulman KI, Herrmann N, Walker SE Current place of monoamine oxidase inhibitors in the treatment of depression CNS Drugs, 2013.PMID 23934742
3. [3]Fiedorowicz JG, Swartz KL The role of monoamine oxidase inhibitors in current psychiatric practice J Psychiatr Pract, 2004.PMID 15552546
4. [4]Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression Arch Gen Psychiatry, 1988.PMID 3276282
5. [5]McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report Am J Psychiatry, 2006.PMID 16946177
6. [6]Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am J Psychiatry, 2006.PMID 17074942
7. [7]Bodkin JA, Amsterdam JD Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients Am J Psychiatry, 2002.PMID 12411221
8. [8]Amsterdam JD A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder J Clin Psychiatry, 2003.PMID 12633131
9. [9]Lotufo-Neto F, Trivedi M, Thase ME Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression Neuropsychopharmacology, 1999.PMID 10063483
10. [10]Walker SE, Shulman KI, Tailor SA, et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets J Clin Psychopharmacol, 1996.PMID 8889911
11. [11]Van den Eynde V, Gillman PK, Blackwell BB The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles Psychopharmacol Bull, 2022.PMID 35721816
12. [12]Gillman PK Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors J Clin Psychopharmacol, 2011.PMID 21192146
13. [13]Gillman PK Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity Br J Anaesth, 2005.PMID 16051647
14. [14]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664
15. [15]Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM, 2003.PMID 12925718
16. [16]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
17. [17]Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments Can J Psychiatry, 2016.PMID 27486148
18. [18]Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder Can J Psychiatry, 2024.PMID 38711351